Retaklik Injection UAE: Retatrutide Weight Loss Pen Guide

Retaklik Injection UAE: Comprehensive Guide to Retatrutide and Triple Agonist Weight Management

Medical and Editorial Disclosure: Medically Reviewed by Clinical Pharmacotherapy Advisory Board. Last Updated: September 2026.

Medical and Legal Disclaimer: The information provided in this article is for educational, informational, and scientific research contexts only. Retaklik, containing active retatrutide (LY3437943), is an investigational peptide therapy. Retatrutide has not received official commercial prescription approval from the UAE Ministry of Health and Prevention (MOHAP), the US FDA, or the European Medicines Agency (EMA). This content does not constitute medical advice. Always consult a licensed healthcare professional in the UAE before starting or altering any medical weight management protocol.

Introduction and Key Summary

Retaklik injection is a pre-filled delivery device containing Retatrutide, a third-generation peptide therapy designed for metabolic modulation and body weight regulation.

Functioning as a triple receptor agonist, Retaklik targets GLP-1, GIP, and Glucagon receptors simultaneously. This combined action helps manage appetite, improve glycemic response, and accelerate energy expenditure.

Quick Facts Overview

• Active Molecule: Retatrutide (LY3437943)

• Pharmacological Class: Triple Hormone Receptor Agonist (GLP-1, GIP, and Glucagon)

• Administration Route: Subcutaneous Injection (Once Weekly)

• Device Format: Pre-filled Multi-Dose Dial Pen (15 mg or 30 mg capacity)

• Clinical Trial Status: Phase 3 TRIUMPH Clinical Program (Investigational Status)

• Primary Targets: Weight Loss, Lowering HbA1c, Lipid Balance

UAE Regulatory Status and Local Availability

Understanding the regulatory landscape in the United Arab Emirates is essential for patients and researchers evaluating weight management options across Dubai, Abu Dhabi, and the Northern Emirates.

• MOHAP and FDA Approval Status: Retaklik (Retatrutide) remains an experimental molecule undergoing Phase 3 clinical trials globally. It is not currently registered or approved for commercial prescription dispensing by the UAE Ministry of Health and Prevention (MOHAP) or international bodies like the US FDA.

• Prescription Alternatives in the UAE: For residents seeking approved medical weight management treatments in UAE clinics, MOHAP-approved options include single GLP-1 receptor agonists (such as semaglutide, known as Ozempic or Wegovy) and dual GLP-1 and GIP agonists (such as tirzepatide, known as Mounjaro).

• Research Context: Any availability of Retatrutide within the region is limited strictly to registered clinical research protocols, trial sites, or authorized scientific study frameworks.

Core Topic Breakdown: Evolution to Triple Agonism

Retaklik represents a major structural advancement over previous metabolic medications, moving from single-target therapies to multi-receptor activation:

1. Semaglutide (Ozempic/Wegovy): Single agonist targeting GLP-1.

2. Tirzepatide (Mounjaro): Dual Agonist targeting GLP-1 and GIP.

3. Retatrutide (Retaklik): Triple Agonist targeting GLP-1, GIP, and Glucagon.

In published Phase 2 clinical trial data published in the New England Journal of Medicine, Retatrutide demonstrated up to 24.2% mean body weight reduction at 48 weeks in adult participants, setting a benchmark in investigational obesity pharmacotherapy.

Technical Specifications and Features

Retaklik pens are manufactured to provide accurate dosing and ease of use in clinical settings:

• Purity and Formulation: Synthesized peptide formulation reaching high HPLC analytical purity standards of 98 percent or higher.

• Dosing Precision: Integrated dial-a-dose mechanism for step-wise titration protocols.

• Half-Life: Extended plasma half-life of approximately six days, enabling a convenient once-weekly subcutaneous dosing schedule.

• Pen Options: Multi-dose cartridges engineered for sterile, repeated subcutaneous delivery.

How It Works: The Science of Three Hormonal Pathways

Retaklik combines three distinct physiological pathways to manage weight and metabolic function.

• GLP-1 (Glucagon-Like Peptide-1): Acts on brain centers to decrease hunger signals and slow gastric emptying, promoting longer post-meal fullness.

• GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances natural insulin secretion during meals, improves insulin sensitivity, and supports healthier lipid metabolism.

• Glucagon Receptor: The critical addition in Retaklik. It stimulates hepatic lipid breakdown and increases resting metabolic rate, allowing the body to burn more calories even while resting.

Dosing Protocol and Usage Guidelines

Dosage administration in clinical trials follows a structured step-wise titration protocol to allow gastrointestinal adaptation.

• Phase 1: Initiation (Weeks 1 to 4): Begin at a low dose, typically 2 mg weekly, administered subcutaneously on the same designated day each week to establish baseline tolerance.

• Phase 2: Step-Wise Escalation (Weeks 5 to 12): Increase dosage in 2 mg to 4 mg increments every 4 weeks based on clinical tolerance, advancing to 4 mg, 6 mg, and up to 8 mg weekly.

• Phase 3: Therapeutic Target (Week 13 onwards): Reach target therapeutic levels ranging from 8 mg to 12 mg weekly, depending on trial design, protocol guidelines, and individual safety limits.

UAE Climate Storage and Cold-Chain Guidelines

The warm climate in the UAE, where outdoor temperatures frequently exceed 40°C during summer months, requires strict cold-chain handling to prevent peptide degradation.

• Refrigeration Standard: Store unopened Retaklik pens consistently between 2°C and 8°C in a standard refrigerator. Do not place it near the freezer cooling element to prevent accidental freezing.

• In-Use Flexibility: Once in use, pens can be kept at controlled room temperature below 25°C to 30°C for a limited duration of up to 21 to 28 days, kept away from direct sunlight.

• Outdoor and Travel Guidance: When commuting or traveling within the UAE, such as between Dubai and Abu Dhabi, transport the pen in an insulated medical cooling pouch with gel packs. Never leave the pen inside a parked vehicle in the UAE.

Safety Profile, Side Effects, and Precautions

Like all peptide therapeutics targeting metabolic pathways, Retaklik requires careful monitoring and medical oversight.

• Common Side Effects: Mild to moderate gastrointestinal events such as nausea, diarrhea, constipation, and transient vomiting are most frequent during initial dose titration phases.

• Heart Rate Observations: Due to Glucagon receptor engagement, a minor increase in resting pulse rate has been observed in clinical trials, requiring periodic cardiovascular monitoring.

• Contraindications: Persons with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia syndrome type 2 (MEN 2), or a history of severe pancreatitis should avoid using triple-agonist therapies.

Frequently Asked Questions (FAQ)

What is the Retaklik injection used for in the UAE?

Retaklik contains Retatrutide, a triple-agonist peptide used in research settings for weight management, appetite suppression, glycemic control, and metabolic regulation.

Is Retaklik approved by MOHAP in the UAE?

No, Retatrutide is currently undergoing Phase 3 global clinical trials (TRIUMPH program) and is not yet approved by MOHAP or the US FDA for commercial prescription sale in the UAE.

How should Retaklik be stored in the warm UAE climate?

Unopened pens must be kept refrigerated at 2°C to 8°C. During travel in the UAE, use an insulated thermal cooling pouch to prevent exposure to temperatures above 30°C.

How does Retaklik differ from Mounjaro (Tirzepatide)?

Mounjaro targets two receptors (GLP-1 and GIP), whereas Retaklik targets three (GLP-1, GIP, and Glucagon). The addition of glucagon helps boost basal metabolic expenditure and liver fat oxidation.

How is Retaklik administered?

It is administered via subcutaneous injection into the abdomen, thigh, or upper arm once weekly using a pre-filled dial injector pen.